Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen Reports 51-Percent Drop in Revenue, Nearly Doubled Loss for Q4 2004

NEW YORK, Feb. 23 (GenomeWeb News) - Nanogen today reported a 51-percent slide in revenues and an 89-percent increase in its net losses for the fourth quarter of 2004.

The company had slightly more than $1 million in total revenues, down from $2.1 million during the same quarter in 2003. Product revenues were $410,000 for the fourth quarter of 2004, compared to $1.1 million for the prior-year period.

R&D costs for Q4 2004 were $5.2 million, a $700,000 increase in spending from $4.5 million during the same period a year ago.

Nanogen's net loss for the quarter amounted to $11.2 million, or $.31 per share, compared to a net loss of $5.9 million, or $.25 per share, during the fourth quarter of 2003.  

As of Dec. 31, Nanogen had a cash position of $51.9 million. Of that, $15.4 million is in the form of cash and cash equivalents, with the remainder in the form of short-term investments.

The firm's cash holdings benefitted from a $5.7 million cash infusion after it acquired Epoch Biosciences for $97 million in December 2004.

Howard Birndoff, Nanogen's CEO and chairman of the board, said in a statement that his company plans to increase revenues in 2005 by launching three new products that will be based on the product portfolios the company gained following the merger with Epoch, and an April 2004 merger with SynX.

Birndoff said he expected total revenue for 2005 would increase three-fold as compared to 2004.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.